TRV120027 is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1. TRV120027 inhibits angiotensin II-mediated vasoconstriction and increases cardiomyocyte contractility.
Dehydro Olmesartan, deriving from Olmesartan, acts as an angiotensin II receptor (AT1R) antagonist and exhibits potential for the study of high blood pressure [1][2].
Olmesartan impurity, a compound related to Olmesartan, is an angiotensin II receptor (AT1R) antagonist utilized in the study of high blood pressure. Olmesartan (RNH-6270) is the parent compound with similar properties and functions as an AT1R antagonist.
TRV120055, a Gq-biased agonist, demonstrates a 10-fold higher molecular efficacy when tested against the AT1R-Gq fusion protein in comparison to the AT1R-βarr2 fusion protein.
TRV055 is a Gq-biased ligand of the angiotensin II receptor type 1 (AT1R). TRV055 is efficacious in stimulating cellular Gq-mediated signaling. TRV055 can be used to develop the Gq-biased AT1R agonists.